Recent Updates
Recently added Catalysts
ELDN Positive Sentiment

Eledon Pharmaceuticals to Report First Quarter 2023 Financial Results on Thursday, May 11, 2023

Thursday, May 4, 2023 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Eledon Pharmaceuticals has announced plans to release its financial results for Q1 2023 on May 11, 2023. Following the results, the management team will hold a conference call and webcast to discuss the findings at 4:30 p.m. ET. The company focuses on developing therapies that target the CD40 Ligand pathway and is advancing its lead compound, tegoprubart. This event will provide insights into Eledon's performance and future direction.
Price reaction · baseline $2.37 (2023-05-03 close) · hit after-hours · clean, no other ELDN news in the window
day 0 close
+6.3%
day 1
+13.1%
day 3 · peak
+16%

Market Sentiment Analysis

POSITIVE FACTORS

  • Eledon Pharmaceuticals is preparing to release its first quarter financial results, indicating continued corporate activity.
  • The scheduled conference call provides an opportunity for management to share updates and engage with stakeholders.
  • The focus on innovative therapies, including tegoprubart, shows Eledon's commitment to advancing treatments.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+90%
120-day peak, hindsight
Typical move
6.5%
average across 7 past catalysts
Cash runway
~11 mo
Medium dilution risk
Lead asset
AT-1501
Phase 2 · Kidney Transplant Rejection

Full Press Release Details

IRVINE, Calif., May 04, 2023 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN) today announced that it plans to release financial results for the first quarter ended March 31, 2023 on Thursday, May 11, after the close of trading. Eledon’s management team will host a conference call and webcast beginning at 4:30 p.m. ET.
Conference Call and Webcast Details:
Thursday, May 11, 2023 at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time
Toll Free: 888-886-7786
International: 416-764-8658
Conference ID: 11107025
Webcast: https://ir.eledon.com/events-and-presentations/events
After the live webcast, the event will be archived on Eledon’s website for one year.
About Eledon Pharmaceuticals and tegoprubart (formerly AT-1501)
Eledon Pharmaceuticals is a clinical stage biotechnology company using its immunology expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat ALS. The company’s lead compound in development is tegoprubart, an anti-CD40L antibody with high affinity for CD40 Ligand, a well-validated biological target with broad therapeutic potential. Eledon is headquartered in Irvine, CA. For more information, please visit the company’s website at www.eledon.com.
Follow Eledon Pharmaceuticals on social media: LinkedIn; Twitter
stephen@gilmartinir.com
Source: Eledon Pharmaceuticals

Frequently Asked Questions

When will Eledon release its financial results for Q1 2023?

Eledon will release its Q1 2023 financial results on May 11, 2023.

What time is Eledon's conference call on May 11?

The conference call starts at 4:30 p.m. ET on May 11, 2023.

How can I access Eledon's conference call and webcast?

Access the conference call at 888-886-7786 or via webcast on Eledon's website.

What is Eledon's lead compound being developed?

Eledon's lead compound is tegoprubart, an anti-CD40L antibody.

What therapeutic areas does Eledon focus on?

Eledon targets organ transplant protection, rejection prevention, and ALS treatment.

ShareAdd on Google
Tags: ELDN Viatris Investor Conferences Healthcare Eledon Pharmaceuticals tegoprubart Q1 2023 results CD40 ligand financial announcement
Last updated: May 4, 2023

Biotech snapshot

Cash runway
$89M liquidity · $8M/mo burn
~11 mo
Medium dilution risk
Lead asset
AT-1501Phase 2
Kidney Transplant Rejection →

Catalyst track record

+90%
best trade around ELDN's most recent catalyst

Peak hindsight return over a 120-day window, across 7 tracked FDA/PDUFA catalysts for ELDN.

See every catalyst's timing & PoA →